Rapamycin inhibits lung metastasis of B16 melanoma cells through down-regulating alphav integrin expression and up-regulating apoptosis signaling

Cancer Science

Volumn 101, Issue 2, 2010, Pages 494-500

  Yang, Zhuoshun ^a   Lei, Zhang ^a   Li, Bo ^a   Zhou, Yu ^a   Zhang, Gui Mei ^a   Feng, Zuo Hua ^a   Zhang, Biao ^a   Shen, Guan Xin ^a   Huang, Bo ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD51 ANTIGEN; CYCLIN DEPENDENT KINASE 1; FOCAL ADHESION KINASE; PROTEIN BAX; PROTEIN BCL XL; PROTEIN BID; RAPAMYCIN; S6 KINASE; VITRONECTIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; LUNG METASTASIS; MELANOMA B16; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; INTEGRIN ALPHAV; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; PROTEIN-SERINE-THREONINE KINASES; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; SIGNAL TRANSDUCTION; SIROLIMUS;

EID: 75649091540     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01412.x     Document Type: Article

References (57)

1. Nguyen DX, Bos PD, Massagué J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009, 9:274-84.
2. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002, 2:563-72.
3. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer 2002, 2:91-100.
4. Felding-Habermann B. Integrin adhesion receptors in tumor metastasis. Clin Exp Metastasis 2003, 20:203-13.
5. Kuphal S, Bauer R, Bosserhoff AK. Integrin signaling in malignant melanoma. Cancer Metastasis Rev 2005, 24:195-222.
6. Liapis H, Flath A, Kitazawa S. Integrin αvβ3 expression by bone-residing breast cancer metastases. Diagn Mol Pathol 1996, 5:127-35.
7. Pignatelli M, Cardillo MR, Hanby A, Stamp GW. Integrins and their accessory adhesion molecules in mammary carcinomas: loss of polarization in poorly differentiated tumors. Hum Pathol 1992, 23:1159-66.
8. Cooper CR, Chay CH, Pienta KJ. The role of a(v)h(3) in prostate cancer progression. Neoplasia 2002, 4:191-4.
9. Carreiras F, Denoux Y, Staedel C, Lehmann M, Sichel F, Gauduchon P. Expression and localization of av integrins and their ligand vitronectin in normal ovarian epithelium and in ovarian carcinoma. Gynecol Oncol 1996, 62:260-7.
10. Albelda SM, Mette SA, Elder DE. Integrin distribution in malignant melanoma: association of the h3 subunit with tumor progression. Cancer Res 1990, 50:6757-64.
11. Natali PG, Hamby CV, Felding-Habermann B. Clinical significance of a(v)h3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions. Cancer Res 1997, 57:1554-60.
12. Gingras MC, Roussel E, Bruner JM, Branch CD, Moser RP. Comparison of cell adhesion molecule expression between glioblastoma multiforme and autologous normal brain tissue. J Neuroimmunol 1995, 57:143-53.
13. Felding-Habermann B, Fransvea E, O'Toole TE, Manzuk L, Faha B, Hensler M. Involvement of tumor cell integrin alpha v beta 3 in hematogenous metastasis of human melanoma cells. Clin Exp Metastasis 2002, 19:427-36.
14. Voura EB, Ramjeesingh RA, Montgomery AM, Siu CH. Involvement of integrin alpha(v)beta(3) and cell adhesion molecule L1 in transendothelial migration of melanoma cells. Mol Biol Cell 2001, 12:2699-710.
15. Qian F, Zhang ZC, Wu XF, Li YP, Xu Q. Interaction between integrin alpha(5) and fibronectin is required for metastasis of B16F10 melanoma cells. Biochem Biophys Res Commun 2005, 333:1269-75.
16. Popkov M, Rader C, Gonzalez B, Sinha SC, Barbas CF. Small molecule drug activity in melanoma models may be dramatically enhanced with an antibody effector. Int J Cancer 2006, 119:1194-207.
17. Ramos OH, Kauskot A, Cominetti MR. A novel alpha(v)beta (3)-blocking disintegrin containing the RGD motive, DisBa-01, inhibits bFGF-induced angiogenesis and melanoma metastasis. Clin Exp Metastasis 2008, 25:53-64.
18. Gong W, Liu Y, Huang B. Recombinant CBD-HepII polypeptide of fibronectin inhibits alphavbeta3 signaling and hematogenous metastasis of tumor. Biochem Biophys Res Commun 2008, 367:144-9.
19. Mitra SK, Schlaepfer DD. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol 2006, 18:516-23.
20. Gong W, Zhang GM, Liu Y. IFN-gamma withdrawal after immunotherapy potentiates B16 melanoma invasion and metastasis by intensifying tumor integrin alphavbeta3 signaling. Int J Cancer 2008, 123:702-8.
21. Liu Y, Huang B, Yuan Y. Inhibition of hepatocarcinoma and tumor metastasis to liver by gene therapy with recombinant CBD-HepII polypeptide of fibronectin. Int J Cancer 2007, 121:184-92.
22. Manes T, Zheng DQ, Tognin S, Woodard AS, Marchisio PC, Languino LR. αvβ3 integrin expression up-regulates cdc2, which modulates cell migration. J Cell Biol 2003, 161:817-26.
23. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002, 2:161-74.
24. Fridman R, Toth M, Chvyrkova I, Meroueh SO, Mobashery S. Cell surface association of matrix metalloproteinase-9 (gelatinase B). Cancer Metastasis Rev 2003, 22:153-66.
25. Mehlen P, Puisieux A. Metastasis: a question of life or death. Nat Rev Cancer 2006, 6:449-58.
26. Vézina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 1975, 28:721-6.
27. Dilling MB, Dias P, Shapiro DN, Germain GS, Johnson RK, Houghton PJ. Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor. Cancer Res 1994, 54:903-7.
28. Huang S, Liu LN, Hosoi H, Dilling MB, Shikata T, Houghton PJ. p53/p21(CIP1) cooperate in enforcing rapamycin-inducedG (1) arrest andd etermine the cellular response to rapamycin. Cancer Res 2001, 61:3373-81.
29. Ogawa T, Tokuda M, Tomizawa K. Osteoblastic differentiation is enhanced by rapamycin in rat osteoblast-like osteosarcoma (ROS 17/2.8) cells. Biochem Biophys Res Commun 1998, 249:226-30.
30. Shah SA, Potter MW, Ricciardi R, Perugini RA, Callery MP. FRAP-p70s6K signaling is requiredfor pancreatic cancer cell proliferation. J Surg Res 2001, 97:123-30.
31. Hultsch T, Martin R, Hohman RJ. The effect of the immunophilin ligands rapamycin and FK506 on proliferation of mast cells andother hematopoietic cell lines. Mol Biol Cell 1992, 3:981-7.
32. Gottschalk AR, Boise LH, Thompson CB, Quintans J. Identification of immunosuppressant-induced apoptosis in a murine B-cell line andits prevention by bcl-x but not bcl-2. Proc Natl Acad Sci U S A 1994, 91:7350-4.
33. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004, 4:335-48.
34. Yin XM, Ding WX, Gao W. Autophagy in the liver. Hepatology 2008, 47:1773-85.
35. Iwamaru A, Kondo Y, Iwado E. Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells. Oncogene 2007, 26:1840-51.
36. Paglin S, Lee NY, Nakar C. Rapamycin-sensitive pathway regulates mitochondrial membrane potential, autophagy, and survival in irradiated MCF-7 cells. Cancer Res 2005, 65:11061-70.
37. Luan FL, Ding R, Sharma VK, Chon WJ, Lagman M, Suthanthiran M. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int 2003, 63:917-26.
38. Guba M, Von Breitenbuch P, Steinbauer M. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002, 8:128-35.
39. Kobayashi S, Kishimoto T, Kamata S, Otsuka M, Miyazaki M, Ishikura H. Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis. Cancer Sci 2007, 98:726-33.
40. Maeda M, Suga T, Takasuka N, Hoshi A, Sasaki T. Effect of bis(bilato)-1,2-cyclohexanediammineplatinum(II) complexes on lung metastasis of B16-F10 melanoma cells in mice. Cancer Lett 1990, 55:143-7.
41. Kolber DL, Knisely TL, Maione TE. Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor 4. J Natl Cancer Inst 1995, 87:304-9.
42. Hippert MM, O'Toole PS, Thorburn A. Autophagy in cancer: good, bad, or both? Cancer Res 2006, 66:9349-51.
43. Ogier-Denis E, Codogno P. Autophagy: a barrier or an adaptive response to cancer. Biochim Biophys Acta 2003, 1603:113-28.
44. Li B, Lei Z, Lichty BD. Autophagy facilitates major histocompatibility complex class I expression induced by IFN-gamma; in B16 melanoma cells. Cancer Immunol Immunother 2009, 10.1007/s00262-009-0752-1, doi
45. Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci U S A 2008, 105:17414-9.
46. Feldman ME, Apsel B, Uotila A. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 2009, 7:e38.
47. Thoreen CC, Kang SA, Chang JW. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 2009, 284:8023-32.
48. Nemeth JA, Nakada MT, Trikha M. Alpha-v integrins as therapeutic targets in oncology. Cancer Invest 2007, 25:632-46.
49. Gutheil JC, Campbell TN, Pierce PR. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res 2000, 6:3056-61.
50. Patel SR, Jenkins J, Papadopolous N. Pilot study of vitaxin-an angiogenesis inhibitor-in patients with advanced leiomyosarcomas. Cancer 2001, 92:1347-8.
51. Posey JA, Khazaeli MB, DelGrosso A. A pilot trial of Vitaxin, a humanized antivitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer. Cancer Biother Radiopharm 2001, 16:125-32.
52. Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 2009, 10:307-18.
53. Inoki K, Ouyang H, Li Y, Guan KL. Signaling by target of rapamycin proteins in cell growth control. Microbiol Mol Biol Rev 2005, 69:79-100.
54. Wong CW, Lee A, Shientag L. Apoptosis: an early event in metastatic inefficiency. Cancer Res 2001, 61:333-8.
55. Del Bufalo D, Biroccio A, Leonetti C, Zupi G. Bcl-2 overexpression enhances the metastatic potential of a human breast cancer line. FASEB J 1997, 11:947-53.
56. Thomson AW, Turnquist HR, Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 2009, 9:324-37.
57. Janes MR, Fruman DA. Immune regulation by rapamycin: moving beyond T cells. Sci Signal 2009, 2:pe25.